header_image

Overview

header_image

Overview

My goal is to have these antibodies available worldwide, so that everyone has the same options my daughter and family had.

Thomas Gad, Founder of Y-mAbs and father of Daniella, a high-risk neuroblastoma survivor

Our Mission at Y-mAbs

Y-mAbs is a commercial stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

Our Pipeline

See Y-mAbs’ pipeline

Learn more